Haemonetics Corporation (HAE)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Haemonetics Corporation (HAE)
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Insights
Critical company metrics and information
Share Price
$81.19Market Cap
$4.08 BillionTotal Outstanding Shares
50.22 Million SharesTotal Employees
3,657Dividend
No dividendIPO Date
May 9, 1991SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.haemonetics.com
Historical Stock Splits
If you bought 1 share of HAE before December 3, 2012, you'd have 2 shares today.
Execution Date | Split Amount |
---|---|
December 3, 2012 | 2-for-1 |
Cash Flow Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $304.81 Million |
Net Cash Flow, Continuing | $-54.80 Million |
Net Cash Flow From Investing Activities | $-444.56 Million |
Net Cash Flow From Investing Activities, Continuing | $-444.56 Million |
Net Cash Flow From Operating Activities | $84.94 Million |
Net Cash Flow | $-51.72 Million |
Exchange Gains/Losses | $3.08 Million |
Net Cash Flow From Operating Activities, Continuing | $84.94 Million |
Net Cash Flow From Financing Activities, Continuing | $304.81 Million |
Income Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Research and Development | $60.10 Million |
Basic Average Shares | $101.72 Million |
Basic Earnings Per Share | $2.44 |
Net Income/Loss | $123.81 Million |
Selling, General, and Administrative Expenses | $448.59 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $123.81 Million |
Income/Loss From Continuing Operations Before Tax | $158.86 Million |
Cost Of Revenue | $645.09 Million |
Costs And Expenses | $1.20 Billion |
Operating Expenses | $548.76 Million |
Income Tax Expense/Benefit | $35.05 Million |
Revenues | $1.36 Billion |
Diluted Average Shares | $102.85 Million |
Gross Profit | $716.13 Million |
Operating Income/Loss | $167.37 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Attributable To Parent | $123.81 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Depreciation and Amortization | $109.52 Million |
Income Tax Expense/Benefit, Deferred | $-15.16 Million |
Benefits Costs and Expenses | $1.20 Billion |
Diluted Earnings Per Share | $2.41 |
Net Income/Loss Available To Common Stockholders, Basic | $123.81 Million |
Balance Sheet
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Noncurrent Assets | $1.57 Billion |
Inventory | $382.11 Million |
Equity | $878.85 Million |
Intangible Assets | $487.84 Million |
Other Non-current Assets | $781.01 Million |
Other Current Liabilities | $155.40 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities And Equity | $2.53 Billion |
Accounts Payable | $69.24 Million |
Wages | $49.30 Million |
Fixed Assets | $300.48 Million |
Current Assets | $955.90 Million |
Liabilities | $1.65 Billion |
Noncurrent Liabilities | $1.37 Billion |
Equity Attributable To Parent | $878.85 Million |
Assets | $2.53 Billion |
Other Current Assets | $573.80 Million |
Current Liabilities | $273.95 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Haemonetics Corporation (HAE)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.